While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Flipkart also announced its foray into the healthcare sector through the launch of Flipkart Health+
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Subscribe To Our Newsletter & Stay Updated
